f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

RANGER II SFA Cont F/u Study


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P190019 / PAS001
Date Original Protocol Accepted 12/16/2020
Date Current Protocol Accepted  
Study Name RANGER II SFA Cont F/u Study
Device Name Ranger™ Paclitaxel-Coated PTA Balloon Catheter
General Study Protocol Parameters
Study Design Randomized Clinical Trial
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives Continued follow-up of premarket cohort: RCT
Study Population Test: Ranger DCB
Control: PTA
Sample Size 376
Key Study Endpoints The primary effectiveness endpoint is primary patency of the target lesion at 24 months.

The primary safety endpoint is a composite of freedom from device- and procedure-related death at 30 days and freedom from target limb major amputation and clinically-driven target lesion revascularization (CD-TLR) at 24 months.

The endpoints to be assessed through 5 years post-procedure are rate of: (1) major adverse events (MAE), (2) clinically-driven target lesion revascularization (CD-TLR), (3) all TLR, (4) clinically-driven target vessel revascularization (CD-TVR), (5) target limb major amputation, (6) arterial thrombosis and (7) mortality status. The endpoints to be assessed at 2 and 3 years post-procedure are: (1) patency, (2) change in ankle-brachial index (ABI), (3) change in walking impairment questionnaire (WIQ), (4) change in walking distance, (5) change in Rutherford classification, and (6) change in quality of life assessment by EQ-5D questionnaire.
Follow-up Visits and Length of Follow-up 5 years


RANGER II SFA Cont F/u Study Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 04/30/2021 04/29/2021 On Time
1 year report 10/30/2021 11/01/2021 Overdue/Received
18 month report 04/30/2022 04/29/2022 On Time
2 year report 10/30/2022 10/27/2022 On Time
3 year report 10/30/2023 10/26/2023 On Time
final report 02/29/2024 02/23/2024 On Time


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-